“Disease-modifying” drugs in rheumatoid arthritis
Identifieur interne : 003502 ( Main/Exploration ); précédent : 003501; suivant : 003503“Disease-modifying” drugs in rheumatoid arthritis
Auteurs :Source :
- Drug and Therapeutics Bulletin [ 0012-6543 ] ; 1985-12-30.
English descriptors
- Teeft :
Abstract
Rheumatoid arthritis (RA) is a systemic inflammatory disease whose major feature is a destructive peripheral polyarthritis. In this condition simple analgesics may relieve pain while non-steroidal anti-inflammatory drugs (NSAIDs) can reduce swelling and stiffness; neither however change the activity or rate of progression of the disease.1 If these drugs fail to control symptoms, if there is radiological evidence of rapid or progressive joint damage, or if the patient has serious extra-articular manifestations of RA (e.g. lung disease, vasculitis, amyloidosis), it is usual to start a drug that might modify the disease or induce remission. This article discusses disease-modifying drugs (DMDs) and how to choose between them.
Url:
DOI: 10.1136/dtb.23.26.101
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000274
- to stream Istex, to step Curation: 000274
- to stream Istex, to step Checkpoint: 002261
- to stream Main, to step Merge: 003576
- to stream Main, to step Curation: 003502
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">“Disease-modifying” drugs in rheumatoid arthritis</title></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8432DE1C15B356706DED5187BA8694B6425946F5</idno><date when="1985" year="1985">1985</date><idno type="doi">10.1136/dtb.23.26.101</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-6XZN9VXZ-0/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000274</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000274</idno><idno type="wicri:Area/Istex/Curation">000274</idno><idno type="wicri:Area/Istex/Checkpoint">002261</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002261</idno><idno type="wicri:Area/Main/Merge">003576</idno><idno type="wicri:Area/Main/Curation">003502</idno><idno type="wicri:Area/Main/Exploration">003502</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">“Disease-modifying” drugs in rheumatoid arthritis</title></analytic><monogr></monogr><series><title level="j">Drug and Therapeutics Bulletin</title><title level="j" type="abbrev">DTB</title><idno type="ISSN">0012-6543</idno><idno type="eISSN">1755-5248</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="1985-12-30">1985-12-30</date><biblScope unit="volume">23</biblScope><biblScope unit="issue">26</biblScope><biblScope unit="page" from="101">101</biblScope></imprint><idno type="ISSN">0012-6543</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0012-6543</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Azathioprine</term><term>Cyclophosphamide</term><term>Maintenance treatment</term><term>Penicillamine</term><term>Rheum</term><term>Simple analgesics</term><term>Sulphasalazine</term><term>Therapeutics bulletin</term><term>Unwanted effects</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Rheumatoid arthritis (RA) is a systemic inflammatory disease whose major feature is a destructive peripheral polyarthritis. In this condition simple analgesics may relieve pain while non-steroidal anti-inflammatory drugs (NSAIDs) can reduce swelling and stiffness; neither however change the activity or rate of progression of the disease.1 If these drugs fail to control symptoms, if there is radiological evidence of rapid or progressive joint damage, or if the patient has serious extra-articular manifestations of RA (e.g. lung disease, vasculitis, amyloidosis), it is usual to start a drug that might modify the disease or induce remission. This article discusses disease-modifying drugs (DMDs) and how to choose between them.</div></front></TEI><affiliations><list></list><tree></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003502 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003502 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8432DE1C15B356706DED5187BA8694B6425946F5
|texte= “Disease-modifying” drugs in rheumatoid arthritis
}}
| This area was generated with Dilib version V0.6.33. |  |